Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven
cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the …

Introduction No therapy has proven to be effective yet to reduce mortality and/or invasive
mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with …

Introduction No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients
with severe COVID-19 could be an effective treatment. Method We conducted a …

Abstract Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …

Background Due to the lack of proven therapies, we evaluated the effects of early
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …

Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

Abstract Objective To determine if Tocilizumab treatment in patients hospitalized with
laboratory confirmed SARS-CoV-2 infection and subsequent COVID-19 disease provides …

Importance Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory
distress, thought to be mediated by cytokine release. Elevated proinflammatory markers …